Research programme: metabolic disorder therapeutics - Zafgen

Drug Profile

Research programme: metabolic disorder therapeutics - Zafgen

Alternative Names: ZGN 839; ZGN-201

Latest Information Update: 14 Nov 2016

Price : $50

At a glance

  • Originator Zafgen
  • Class Small molecules
  • Mechanism of Action Methionine aminopeptidase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Obesity
  • Discontinued Non-alcoholic steatohepatitis

Most Recent Events

  • 01 Oct 2016 Discontinued - Preclinical for Non-alcoholic steatohepatitis in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in USA (PO)
  • 30 Jun 2014 Preclinical trials in Non-alcoholic steatohepatitis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top